Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection



Status:Completed
Conditions:Infectious Disease, Hepatitis, Hepatitis
Therapuetic Areas:Immunology / Infectious Diseases
Healthy:No
Age Range:3 - 17
Updated:9/28/2018
Start Date:July 7, 2014
End Date:September 13, 2018

Use our guide to learn which trials are right for you!

A Phase 2, Open-Label, Multicenter, Multi-cohort, Single-Arm Study to Investigate the Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection

This study will have two parts as follows:

The PK Lead-in Phase of the study will evaluate the steady state pharmacokinetics (PK) and
confirm the dose of sofosbuvir (SOF) in hepatitis C virus (HCV)-infected pediatric
participants. The PK Lead-in Phase will also evaluate the safety and tolerability of 7 days
of dosing of SOF+ribavirin (RBV) in HCV-infected pediatric participants.

The Treatment Phase will be initiated by age cohort after confirmation of age-appropriate SOF
dosage levels. Participants from the PK Lead-in Phase will immediately rollover into the
Treatment Phase with no interruption of study drug administration. The Treatment Phase will
evaluate the antiviral efficacy, safety, and tolerability of SOF+RBV for 12 or 24 weeks in
pediatric participants with genotype 2 or 3 HCV infection, respectively.


Key Inclusion Criteria:

- Consent of parent or legal guardian required

- Chronic HCV infection genotype 2 or 3

- Screening laboratory values within defined thresholds

- PK Lead-in only: all individuals must be treatment naive

Key Exclusion Criteria:

- History of clinically significant illness or any other medical disorder that may
interfere with subject treatment, assessment or compliance with the protocol

- Co-infection with HIV, acute hepatitis A virus, or hepatitis B virus

- Clinical hepatic decompensation (ie, ascites, encephalopathy or variceal hemorrhage)

- Pregnant or nursing females

- Known hypersensitivity to study medication

- Use of any prohibited concomitant medications as within 28 days of the Day 1 visit

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
We found this trial at
17
sites
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
1919
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
2301
mi
from 91732
Baltimore, MD
Click here to add this to my saved trials
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
1225
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
1194
mi
from 91732
Fort Worth, TX
Click here to add this to my saved trials
2103
mi
from 91732
Gainesville, FL
Click here to add this to my saved trials
1793
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
2122
mi
from 91732
Morgantown, WV
Click here to add this to my saved trials
1763
mi
from 91732
Nashville, TN
Click here to add this to my saved trials
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
355
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
964
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
7523
mi
from 91732
Westmead,
Click here to add this to my saved trials